Abstract |
Results of treatment of 44 patients with disseminated non-seminomatous testicular tumors versus advancement are discussed in the paper. In cases of minimal and moderate advancement (group 1), induction chemotherapy included three cycles of VAB-6 regimen ( vinblastine, actinomycin D, bleomycetin, cyclophosphamide plus 120 mg/m2 platidiam) whereas cases of advanced tumor (group 2) received six such cycles; two of them used 150 mg/m2 platidiam dropwise in a 3% sodium chloride solution. Complete regression was observed in 22 of 24 (96.1%) patients of group 1 and in seven out of 20 (35%) cases of group 2; it was registered in 100, 81.8 and 38% of patients with minimal, moderately- and far-advanced disease, respectively. Patients were followed for 4-23 months (average 14.5 months). Eight cases relapsed. At the time of this writing, 38 out of 44 (86.3%) patients are alive, and 23 out of 29 (79.3%) continue in complete remission. Toxicity was moderate. Application of 3% NaCl prevented nephrotoxicity of high-dose (150 mg/m2) platidiam.
|
Authors | T A Abdyldaev, S A Tiuliandin, S V Batov |
Journal | Voprosy onkologii
(Vopr Onkol)
Vol. 36
Issue 1
Pg. 85-9
( 1990)
ISSN: 0507-3758 [Print] Russia (Federation) |
Vernacular Title | Rezul'taty khimioterapii bol'nykh s disseminirovannymi opukholiami iaichka. |
PMID | 1689527
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Bleomycin
- Chlorambucil
- Dactinomycin
- Vinblastine
- Doxorubicin
- Cyclophosphamide
- Cisplatin
|
Topics |
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bleomycin
(administration & dosage)
- Chlorambucil
(administration & dosage)
- Cisplatin
(administration & dosage)
- Cyclophosphamide
(administration & dosage)
- Dactinomycin
(administration & dosage)
- Doxorubicin
(administration & dosage)
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Neoplasms, Germ Cell and Embryonal
(drug therapy, mortality, pathology)
- Testicular Neoplasms
(drug therapy, mortality, pathology)
- Testis
(pathology)
- Time Factors
- Vinblastine
(administration & dosage)
|